Abstract
Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.
| Original language | English |
|---|---|
| Pages (from-to) | 991-993 |
| Number of pages | 3 |
| Journal | Expert Opinion on Drug Delivery |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- Aflibercept
- Anti-VEGF
- Bevacizumab
- Bilateral intravitreal injection
- Ophthalmology resident
- Ranibizumab
- Teaching institution
- Veterans Affairs hospital
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Safety of bilateral intravitreal injections delivered in a teaching institution. / Chao, Daniel L.; Gregori, Ninel; Khandji, Joyce; Goldhardt, Raquel.
In: Expert Opinion on Drug Delivery, Vol. 11, No. 7, 01.01.2014, p. 991-993.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Safety of bilateral intravitreal injections delivered in a teaching institution
AU - Chao, Daniel L.
AU - Gregori, Ninel
AU - Khandji, Joyce
AU - Goldhardt, Raquel
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.
AB - Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.
KW - Aflibercept
KW - Anti-VEGF
KW - Bevacizumab
KW - Bilateral intravitreal injection
KW - Ophthalmology resident
KW - Ranibizumab
KW - Teaching institution
KW - Veterans Affairs hospital
UR - http://www.scopus.com/inward/record.url?scp=84903220999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903220999&partnerID=8YFLogxK
U2 - 10.1517/17425247.2014.909806
DO - 10.1517/17425247.2014.909806
M3 - Article
C2 - 24815986
AN - SCOPUS:84903220999
VL - 11
SP - 991
EP - 993
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
SN - 1742-5247
IS - 7
ER -